LOCUS BIOSCIENCES
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
LOCUS BIOSCIENCES
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2015-01-01
Address:
Morrisville, North Carolina, United States
Country:
United States
Website Url:
http://www.locus-bio.com
Total Employee:
11+
Status:
Active
Contact:
(919) 495-4510
Total Funding:
128.69 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Board_member
2015-11-01
Advisor
2015-11-01
Board_observer
2017-01-01
Current Employees Featured
Paul Garofolo Co-Founder, Chief Executive Officer, & Chairman of the Board @ Locus Biosciences
Co-Founder, Chief Executive Officer, & Chairman of the Board
2015-05-01
Chase Beisel Co-Founder & Scientific Advisor @ Locus Biosciences
Co-Founder & Scientific Advisor
Dave Ousterout Co-Founder & Chief Scientific Officer @ Locus Biosciences
Co-Founder & Chief Scientific Officer
2016-01-01
Nick Taylor Co-Founder & Project/Program Manager @ Locus Biosciences
Co-Founder & Project/Program Manager
Nick Conley Vice President of Technology, Pharmaceutical Operations and Technology @ Locus Biosciences
Vice President of Technology, Pharmaceutical Operations and Technology
2021-10-01
Charles Gersbach Co-Founder & Scientific Advisor @ Locus Biosciences
Co-Founder & Scientific Advisor
2015-12-01
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-07-17 | EpiBiome | EpiBiome acquired by Locus Biosciences | N/A |
Investors List
Viking Global Investors
Viking Global Investors investment in Series B - Locus Biosciences
Discovery Innovations
Discovery Innovations investment in Series B - Locus Biosciences
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series B - Locus Biosciences
Tencent
Tencent investment in Series B - Locus Biosciences
Artis Ventures (AV)
Artis Ventures (AV) investment in Series B - Locus Biosciences
Hercules Capital
Hercules Capital investment in Debt Financing - Locus Biosciences
CARB-X
CARB-X investment in Grant - Locus Biosciences
North Carolina Biotechnology Center
North Carolina Biotechnology Center investment in Grant - Locus Biosciences
Artis Ventures (AV)
Artis Ventures (AV) investment in Series A - Locus Biosciences
Tencent
Tencent investment in Series A - Locus Biosciences
Official Site Inspections
http://www.locus-bio.com Semrush global rank: 3.79 M Semrush visits lastest month: 3.53 K
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Locus Biosciences"
Home - Locus Biosciences
We are trailblazers in the development of engineered bacteriophage products. Applying modern technologies, we are revolutionizing the treatment of bacterial infections and addressing unmet …See details»
About Us - Locus Biosciences
At Locus Biosciences we are on a mission to change the future of medicine by developing precision medicines that target only the pathogenic bacteria causing an infection, leaving the …See details»
Platform - Locus Bioscience
Central to our mission is LOCUS, a powerful technology-led platform that enables us to develop products that selectively remove bacterial species at equivalent or superior levels than antibiotics without the drawback associated with broad …See details»
Locus Biosciences - Wikipedia
Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina. Locus develops phage therapies based on CRISPR–Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Cas9, delivered by engineered bacteriophages. The intended therapeutic targets are antibiotic-resistant bacterial infections. See details»
Locus Biosciences | NCBioNetwork.org
Locus Biosciences is a clinical-stage biotechnology company developing CRISPR-enhanced precision antibacterial products (crPhage™) to address critical unmet medical needs in bacterial infections and microbiome indications …See details»
Locus Bio-Energy
Take oilfield operations to new levels of performance, profitability and sustainability with Locus Bio-Energy’s ESG-friendly and low-carbon biosurfactants–tailored to upstream and midstream oil and gas applications.See details»
Locus Biosciences, Inc. - LinkedIn
Locus Biosciences is a clinical-stage biotechnology company developing engineered bacteriophage products to address critical unmet medical needs in bacterial infections and …See details»
Company: Locus Biosciences - crisprmedicinenews.com
Locus Biosciences is a clinical-stage gene-editing company focused on treating bacterial infectious diseases. The company uses its next generation sequencing-based platform to rapidly identify new bacterial targets and phages. Locus …See details»
Veteran Oil Industry Executive Jonathan Rogers Joins …
SOLON, Ohio—January 21, 2019—Jon Rogers, a highly respected global oilfield executive who served in senior roles at BP and Clariant, has been named CEO of Locus Bio-Energy Solutions ™ (Locus Bio-Energy), a disruptive technology …See details»
Locus Biosciences Announces $23.9 Million in Funding from …
Jan 23, 2024 · RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new …See details»
Contact - Locus Biosciences
Precision Medicines for Bacterial Infections and Immunologic Diseases. Home. Platform. Programs. Manufacturing. Careers. About Us. Newsroom. Contact UsSee details»
Home | Locus Fermentation Solutions (Locus FS)
Locus FS, the biosurfactant company, develops award-winning green solutions customized to outperform chemicals and help solve profitability, sustainability and ESG challenges in global …See details»
Locus Biosciences Company Profile - Office Locations ... - Craft
Locus Biosciences is a pharmaceutical company that provides antibiotic resistance solutions. It develops precision medicines that target only the pathogenic bacteria causing an infection. …See details»
Locus Bio S.A. / Loci Labs - BIO International Convention | BIO
Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.See details»
Locus Biosciences Secures Financing of up to $25 Million
Oct 19, 2021 · Locus Biosciences is creating a new class of precision biotherapeutics with clinical-stage, engineered bacteriophage treatments for a diverse set of bacterial and inflammatory …See details»
Selected As Best Sustainable Energy Company | Energy Awards
Dec 8, 2021 · Oil innovation company was awarded the honor by the 2021 World Finance Energy Awards for its biosurfactants that boost production rates and slow declines, while helping …See details»
Locus Biomanufacturing Solutions Facility
Locus built an ISPE 2021 Facility of the Year award-winning, world-class biologics manufacturing facility, enabling the manufacture of precision therapeutics while providing the capability to …See details»
Locus Bio-Energy Solutions - Org Chart, Teams, Culture & Jobs
Locus Bio-Energy Solutions® (Locus BE) offers high-performance and low-CAPEX green biosurfactant solutions to the oil & gas industry’s most persistent financial and ESG …See details»
The enhancer module of Integrator controls cell identity and early ...
2 days ago · The assays were run in a CFK96 Real-Time system (Bio-Rad) using the following parameters: 3 min at 95 °C, 40 cycles of 10 s at 95 °C, 20 s at 63 °C and 30 s at 72 °C. …See details»
Newsroom - Locus Biosciences
Locus Biosciences Announces Positive Results from Part 1 of ELIMINATE Phase 2 Trial of the Engineered Bacteriophage Therapy LBP-EC01 Published in The Lancet Infectious DiseasesSee details»